Home > Resources > Company Profiles > Cerus Corporation

Cerus Corporation (CERS)

EMAIL
PRINT
SHARE
TEXT SIZE:
SHARE
Send a copy to me

Separate multiple email addresses (max 20) with commas.

0/1500
Claes Glassell , CEO/President/Director
Industry: Healthcare
OPEN
LAST
$
PREV CLOSE
CHANGE
VOLUME


Overview
News
People
Financials

Company Information

Claes Glassell, CEO/President/Director

2411 Stanwell Drive

Concord, CA 94520

US Map it

Phone: (925) 288-6000

Fax: (925) 603-9099

www.cerus.com



Overview

A biomedical products company, which focuses on commercializing the INTERCEPT Blood System to enhance blood safety.

Employees

Number of Employees: 111
Revenue per Employee: $218,234

Top Executives

William M. Greenman, President, Subsidiary
William J. Dawson, Vice President, Divisional/CFO
Howard G. Ervin, Vice President, Divisional

Dr. Laurence M. Corash, M.D., Founder/Chief Medical Officer/Director/Senior VP

Board of Directors

Bruce C. Cozadd, Director
Timothy B. Anderson, Director
William R. Rohn, Director

Gail Gaumer Schulze, Director
Dr. Laurence M. Corash, M.D., Founder/Chief Medical Officer/Director/Senior VP
B. J. Cassin, Chairman of the Board/Director

Financials

Quarterly
Annual

Income Statement 10/2008 09/2008 05/2008 03/2008
Sales 1.73 Mil. 2.93 Mil. 1.6 Mil. 0
Gross Operating Profit 2.16 Mil. 1.1 Mil. 3.36 Mil. 2.76 Mil.
Operating Income before D & A (EBITDA) -7.39 Mil. -9.01 Mil. -6.52 Mil. 2.76 Mil.
Total Income Before Interest Expenses (EBIT) -7.58 Mil. -9.09 Mil. -5.29 Mil. 2.76 Mil.
Total Net Income -8.82 Mil. -9.09 Mil. -5.29 Mil. -11.33 Mil.
Basic EPS, Total -0.27 -0.28 -0.16 -0.36
Diluted EPS, Total -0.27 -0.28 -0.16 -0.36

BALANCE STATEMENT 10/2008 09/2008 05/2008 03/2008
Cash and Equivalents 15.31 Mil. 22.4 Mil. 21.74 Mil. 19.62 Mil.
Total Assets 48 Mil. 59.67 Mil. 65.38 Mil. 73.9 Mil.
Total Liabilities 12.57 Mil. 16.18 Mil. 13.79 Mil. 18.32 Mil.
Total Capitalization 39.6 Mil. 47.81 Mil. 56.01 Mil. 59.89 Mil.

Cash Flow 10/2008 09/2008 05/2008 03/2008
Net Cash From Continuing Operations -28.09 Mil. -18.56 Mil. -10.7 Mil. -37.4 Mil.
Net Cash From Investing Activities 22.4 Mil. 20.04 Mil. 12.11 Mil. 9.3 Mil.
Net Cash From Financing Activities 1.37 Mil. 1.3 Mil. 710 K. 1.44 Mil.
Net Change in Cash & Cash Equivalents -4.32 Mil. 2.78 Mil. 2.12 Mil. -26.66 Mil.

powered by Interactive Data

Income Statement 2008 2007 2006 2005
Sales 4.45 Mil. 825 K. -652 K. -2.15 Mil.
Gross Operating Profit 6.59 Mil. 34.76 Mil. 25.02 Mil. 16.06 Mil.
Operating Income before D & A (EBITDA) -32.94 Mil. -8.76 Mil. -8.69 Mil. -21.81 Mil.
Total Income Before Interest Expenses (EBIT) -39.1 Mil. -4.78 Mil. 13.06 Mil. -25.17 Mil.
Total Net Income -45.3 Mil. -4.78 Mil. 13.06 Mil. -31.15 Mil.
Basic EPS, Total -1.42 -0.18 0.58 -1.41
Diluted EPS, Total -1.42 -0.18 0.55 -1.41

BALANCE STATEMENT 2008 2007 2006 2005
Cash and Equivalents 19.62 Mil. 46.29 Mil. 5.78 Mil. 39.17 Mil.
Total Assets 73.9 Mil. 102.74 Mil. 51 Mil. 99.87 Mil.
Total Liabilities 18.32 Mil. 14.81 Mil. 23.32 Mil. 76.09 Mil.
Total Capitalization 59.89 Mil. 100.97 Mil. 35.28 Mil. 25.99 Mil.

Cash Flow 2008 2007 2006 2005
Net Cash From Continuing Operations -37.4 Mil. -14.68 Mil. -14.95 Mil. -12.73 Mil.
Net Cash From Investing Activities 9.3 Mil. -7.94 Mil. 15.36 Mil. 28.52 Mil.
Net Cash From Financing Activities 1.44 Mil. 63.13 Mil. -33.81 Mil. 207 K.
Net Change in Cash & Cash Equivalents -26.66 Mil. 40.51 Mil. -33.39 Mil. 16 Mil.

powered by Interactive Data







Related Companies by Market Cap
Company Name
Price
Change
Market Cap
Targanta Therapeutics Corporation
198.79 Mil.
Altus Pharmaceuticals, Incorporated
200.69 Mil.
Chelsea Therapeutics International, Incorporated
194.16 Mil.
Repligen Corporation
201.88 Mil.

Company Profile Change Request

The data provided in our company profiles comes from third party information providers.

Also in Portfolio.com
Most Read
Most Emailed
Recently Commented